Statements (69)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:biotechnology
|
| gptkbp:aims_to |
improve patient outcomes
|
| gptkbp:awards |
various industry awards
|
| gptkbp:business_model |
biotech startup
|
| gptkbp:ceo |
gptkb:Dr._John_M._Mc_Carty
|
| gptkbp:clinical_trial |
ongoing
Phase 1 Phase 2 Phase 3 multiple sites published in journals adaptive trials promising outcomes |
| gptkbp:collaborates_with |
academic institutions
|
| gptkbp:collaborations |
leading universities
|
| gptkbp:community_engagement |
patient advocacy groups
|
| gptkbp:develops |
gptkb:AV-101
gptkb:Zy_T-101 |
| gptkbp:eligibility |
ongoing trials
|
| gptkbp:employs |
scientists and researchers
|
| gptkbp:engages_in |
clinical research
|
| gptkbp:focuses_on |
rare diseases
therapeutics for kidney diseases |
| gptkbp:founded |
gptkb:2018
|
| gptkbp:funding |
gptkb:venture_capital
secured funding |
| gptkbp:future_plans |
expand into new markets
|
| gptkbp:global_presence |
international collaborations
|
| gptkbp:has_advisory_board |
experts in the field
|
| gptkbp:has_collaborations_with |
biopharmaceutical companies
|
| gptkbp:head_of_state |
strategic partnerships
|
| gptkbp:headquarters |
gptkb:San_Diego,_California
|
| gptkbp:healthcare |
cutting-edge research
|
| https://www.w3.org/2000/01/rdf-schema#label |
Zy Versa Therapeutics
|
| gptkbp:instruction_set |
multiple drug candidates
|
| gptkbp:invention |
multiple patents
|
| gptkbp:investment |
high
research and development institutional investors transparent communication |
| gptkbp:investment_focus |
biologics and small molecules
|
| gptkbp:is_a_platform_for |
innovative drug delivery systems
|
| gptkbp:marketing_strategy |
targeted therapies
|
| gptkbp:mission |
to develop innovative therapies
|
| gptkbp:partnership |
various pharmaceutical companies
|
| gptkbp:partnerships |
available
collaborative research |
| gptkbp:patient_centric_approach |
focus on patient needs
|
| gptkbp:product |
innovative solutions
|
| gptkbp:products |
Zy Versa's lead product candidate
|
| gptkbp:publications |
peer-reviewed articles
|
| gptkbp:regulatory_compliance |
ongoing
FDA approved |
| gptkbp:research_areas |
nephrology
|
| gptkbp:research_focus |
chronic kidney disease
inflammation and fibrosis |
| gptkbp:side_effect |
improving quality of life
|
| gptkbp:social_responsibility |
community support initiatives
|
| gptkbp:stock_exchange |
gptkb:true
|
| gptkbp:stock_symbol |
ZVSA
|
| gptkbp:strategic_goals |
expand product pipeline
|
| gptkbp:sustainability_practices |
environmentally responsible
|
| gptkbp:team |
experienced professionals
|
| gptkbp:traded_on |
gptkb:NASDAQ
|
| gptkbp:utilizes |
proprietary technology
|
| gptkbp:vision |
to transform treatment paradigms
|
| gptkbp:website |
www.zyversatherapeutics.com
|
| gptkbp:bfsParent |
gptkb:Alaunos_Therapeutics
|
| gptkbp:bfsLayer |
5
|